Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

reiter's syndrome2 - concentrated urine1 - castration-resistant prostate cancer5 - demeclocycline1 - psa velocity1 - adrenocortical carcinoma1 - lower urinary tract symptomս1 - severe hypocitraturia1 - femoral artery1 - reduced potassium secretion1 - denosumab1 - cardiovascular issues1 - biomarker1 - renal tubules1 - kidney stone surgery1 - routine antenatal sonography1 - purple1 - testosterone6 - ket1 - robotic stereotactic radiosurgery1 - blood stream infection1 - enterocele5 - nephron-sparing surgery1 - liver transplant1 - minimal glomerular lesions1 - cryptorchidism1 - early stage prostate cancer1 - body mass index2 - low-dose prednisone1 - sacrum1 -